|
The history of AIDS (Acquired Immunodeficiency Syndrome), with timelines, photos, and links to resources on the Internet. Endeavoring to raise public awareness through understanding.
|
|
The History of AIDS: Timeline of the History of HIV/AIDS: 1999 1999 Mepron (atovaquone, Glaxo Wellcome) Suspension was approved on January 5, 1999 for the prevention of Pneumocystis carinii pneumonia (PCP). Panretin (alitretinoin) gel 0.1% was approved on February 2, 1999 for the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. The manufacturer is Ligand Pharmaceuticals. Approval Letter | Approved Labeling On February 17, 1999, a Businessman was Sentenced to Over Five Years for Selling Bogus HIV-Testing Kits February, 1999 - Glass Capillary Tubes: Joint Safety Advisory About Potential Risks. This document discusses the potential risk of injury and/or infection from bloodborne pathogens, including HIV, hepatitis B and hepatitis C viruses, due to the accidental breakage of glass capillary tubes, and to recommend certain steps that can minimize the risk. On March 2, 1999, FDA approved a supplement to AMPLICOR HIV-1 MONITOR Test (Roche Molecular Systems, Inc.). This supplemental approval extends the lower limit of quantitation from 400 HIV RNA copies/mL down to 50 copies/mL; the upper limit of quantitation, 750,000 HIV RNA copies/mL remains the same. It is intended for use in conjunction with clinical presentation and other laboratory markers of disease progress for the clinical management of HIV-1 infected patients. On the same date, another supplement was approved for patient monitoring and it can be used as an aid in management of patients on anti-viral therapy for HIV disease. The original application, approved June 3, 1996, was for disease prognosis in conjunction with clinical presentation and other laboratory markers. (Labeling, 53 pages in PDF) On March 29, 1999, Kenneth Thiefault and his wife Mardol Barber were sentenced in a Florida court for their conviction last year on conspiracy, distribution of an Ozone Generator, mail fraud, wire fraud, and tax violations. The court sentenced Mr. Thiefault to 72 months of incarceration (to be followed by 3 years of supervised release), imposed a $100,000 fine, and ordered payment of $14,400 in restitution. The court sentenced the Ms. Barber to 33 months of incarceration (to be followed by 3 years of supervised release) and imposed a fine of $60,000. Additionally, the court ordered both defendants to help the IRS compute their back taxes and banned both defendants from participating in any securities or telemarketing businesses in the future. The couple were making claims that the ozone generators can oxidize toxins in the body and cure everything from gangrene to cancer to AIDS. On April 15, 1999, FDA granted accelerated approval to Agenerase (amprenavir, Glaxo Wellcome, Inc.) 50 mg, 150 mg capsules and oral solution. Agenerase is a protease inhibitor that is indicated, in combination with other antiretroviral agents, for the treatment of HIV-1 infection. This indication is based on analyses of plasma HIV RNA levels and CD4 cell counts in controlled studies of up to 24 weeks in duration. At present, there are no results from controlled trials evaluating long-term suppression of HIV RNA or disease progression with Agenerase. On June 29, 1999, FDA granted marketing approval for Norvir (ritonavir, Abbott Laboratories) 100 mg soft gelatin capsules. On August 17, 1999, FDA issued a final rule on OTC Drug Products Containing Colloidal Silver declaring that all OTC drug products containing colloidal silver or silver salts are not recognized as safe and effective and are misbranded. Colloidal silver is a suspension of silver particles in a colloidal (gelatinous) base. In recent years, colloidal silver preparations of unknown formulation have been appearing in stores for the treatment of HIV/AIDS and other life threatening diseases. On December 10, 1999, FDA took Action Against a Firm Marketing Unapproved Drugs, MGN-3, a rice bran extract, as a treatment for cancer and HIV. 1998 ...Last ||| Next... 2000 |